Cardiac glycosides are not associated with increased mortality or hospitalization rates in ICD and CRT-ICD patients after adjustment for baseline-characteristics at one-year follow-up: Results from the German DEVICE registry
Despite lacking supporting randomized trials, cardiac glycosides (CGs) are widely used in heart failure and/or atrial fibrillation. Moreover, several pro- and retrospective studies and registry- data have recently raised serious concerns in terms of efficacy and safety of CGs in this field. We have therefore examined the association between CGs and clinical outcome of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization (CRT-ICD) patients of the large German DEVICE registry.
Source: International Journal of Cardiology - Category: Cardiology Authors: Niklas Bode, Matthias Hochadel, Dietrich Andresen, Ralf Zahn, Stefan G. Spitzer, Johannes Brachmann, Christoph Stellbrink, Werner Jung, Bernd-Dieter Gonska, Florian Reinke, Jochen Senges, Lars Eckardt Source Type: research
More News: Atrial Fibrillation | Cardiology | Germany Health | Heart | Heart Failure | Nutrition | Study